Related Experiment Video
Updated: Aug 7, 2026
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
Interventional strategies to prevent beta-cell apoptosis in islet transplantation
Juliet A Emamaullee1, A M James Shapiro
1Surgical Medical Research Institute, University of Alberta, Edmonton, AB T6G 2N8. juliete@ualberta.ca
Abstract:
A substantial proportion of the transplanted islet mass fails to engraft due to death by apoptosis, and a number of strategies have been explored to inhibit beta-cell loss. Inhibition of extrinsic signals of apoptosis (i.e., cFLIP or A20) have been explored in experimental islet transplantation but have only shown limited impact. Similarly, strategies targeted at intrinsic signal inhibition (i.e., BCL-2) have not yet provided substantial improvement in islet engraftment. Recently, investigation of downstream apoptosis inhibitors that block the final common pathway (i.e., X-linked inhibitor of apoptosis protein [XIAP]) have demonstrated promise in both human and rodent models of engraftment. In addition, XIAP has enhanced long-term murine islet allograft survival. The complexities of both intrinsic and extrinsic apoptotic pathway inhibition are discussed in depth.
Insights
Blocking the final common pathway of apoptosis with X-linked inhibitor of apoptosis protein (XIAP) shows promise for improving transplanted islet engraftment and survival. This approach may overcome limitations of targeting earlier apoptotic signals.
Area of Science:
- Cellular biology
- Immunology
- Transplantation science
Background:
- Transplanted islet cell loss due to apoptosis significantly hinders engraftment success.
- Strategies targeting extrinsic (e.g., cFLIP, A20) and intrinsic (e.g., BCL-2) apoptosis pathways have yielded limited improvements in islet engraftment.
- The final common pathway of apoptosis presents a potential target for enhancing islet survival.
Purpose of the Study:
- To evaluate the efficacy of inhibiting the final common pathway of apoptosis using X-linked inhibitor of apoptosis protein (XIAP) in islet transplantation.
- To explore XIAP's potential to improve islet engraftment and long-term allograft survival.
Main Methods:
- Investigated downstream apoptosis inhibitors, specifically XIAP.
- Examined XIAP's effects in both human and rodent models of islet engraftment.
- Assessed long-term murine islet allograft survival with XIAP intervention.
Main Results:
- XIAP demonstrated promise in both human and rodent islet engraftment models.
- XIAP significantly enhanced long-term survival of murine islet allografts.
- Targeting the final common pathway offers a more effective strategy than inhibiting earlier apoptotic signals.
Conclusions:
- Inhibition of the final common apoptotic pathway via XIAP is a promising strategy for improving islet transplantation outcomes.
- XIAP represents a potential therapeutic target to enhance beta-cell survival and islet engraftment.
- Further research into XIAP's role is warranted for optimizing islet transplantation protocols.
